Correlation of Visual Prostate Symptom Score with International Prostate Symptom Score and Uroflowmetry Parameters in Nepalese Male Patients withLower Urinary Tract Symptoms
Introduction: International prostate symptom score is a validated questionnaire used to evaluate the lower urinary tract symptoms in benign prostatic hyperplasia. Visual prostate symptom score is a new simplified symptom score with pictograms to evaluate the same. We evaluated the correlation of visual prostate symptom score with international prostate symptom score and uroflowmetry parameters in Nepalese male patients with lower urinary tract symptoms.
Methods: Male patients aged ≥40 years attending the Urology clinic were enrolled in the study. They were given international prostate symptom score and visual prostate symptom score questionnaires to complete providing assistance whenever needed. Demographic data, examination findings and uroflowmetry parameters were noted. Correlation and regression analysis was used to identify correlation of the two scoring systems and uroflowmetry parameters.
Results: Among the 66 patients enrolled, only 10 (15.15%) patients were able to understand English language. There was a statistically significant correlation between total visual prostate symptom score and international prostate symptom score (r= 0.822; p<0.01). The correlations between individual scores of the two scoring systems related to force of urinary stream, frequency, nocturia and quality of life were also statistically significant. There was also a statistically significant correlation of both scores with maximum flow rate and average flow rate.
Conclusions: There is a statistically significant correlation of visual prostate symptom score with international prostate symptom score and uroflowmetry parameters. IPSS can be replaced with simple VPSS in evaluation of lower urinary tract symptoms in elderly male patients.
Keywords: correlation; international prostate symptom score; lower urinary tract symptoms; uroflowmetry; visual prostate symptom score. [PubMed]
2. Rodrigues Netto N Jr, de Lima ML, de Andrade EF. Latin American study on patient acceptance of the International Prostate Symptom Score (IPSS) in the evaluation of symptomatic benign prostatic hyperplasia. Urology. 1997;49(1):46-9. [PubMed | Full Text]
3. van der Walt CL, Heyns CF, Groeneveld AE, et al. Prospective comparison of a new visual prostate symptom score versus the international prostate symptom score in men with lower urinary tract symptoms. Urology. 2011;78:17-20. [PubMed | Full Text]
4. Park YW, Lee JH. Correlation between the visual prostate symptom score and international prostate symptom score in patients with lower urinary tract symptoms. Int Neurourol J. 2014;18:37-41. [PubMed | Full Text]
5. Heyns CF, van der Walt CL, Groeneveld AE. Correlation between a new visual prostate symptom score (VPSS) and uroflowmetry parameters in men with lower urinary tract symptoms. S Afr Med J. 2012;102:237-40. [PubMed]
6. Andika A, Yogi IG, Hari N. Comparison between visual prostate symptom score and international prostate symptom score in males older than 40 years in rural Indonesia. Prostate Int. 2014;2(4):176-81. [Full Text]
7. Heyns CF, Steenkamp BA, Chiswo J, et al. Evaluation of the visual prostate symptom score in a male population with great language diversity and limited education: a study from Namibia. S Afr Med J. 2014;104:353-7. [PubMed]
8. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793-803. [PubMed]
9. Bailey A, Martin ML, Girman C. Development of a multiregional United States Spanish version of the International Prostate Symptom Score and the Benign Prostatic Hyperplasia impact index. J Urol. 2005;174:1896-1901. [PubMed]
10. Baida X, Garcia-Losa M, Dal-Re R. Ten-language translation and harmonization of the International Prostate Symptom Score: developing a methodology for multinational clinical trials. Eur Urol. 1997;31:129-40. [PubMed]
11. MacDiarmid SA, Goodson TC, Holmes TM, et al. An assessment of the comprehension of the American Urological Association Symptom Index. J Urol. 1998;159:873-4. [PubMed]
12. Cam K. BPH: how useful is a visual prostate symptom score for patients? Nat Rev Urol. 2011;8:536-7. [PubMed]
13. Netto Junior NR, de Lima ML. The influence of patient education level on the International Prostatic Symptom Score. J Urol. 1995;154:97-9. [PubMed]
14. Huh JS, Kim YJ, Kim SD. Prevalence of benign prostatic hyperplasia on Jeju Island: analysis from a cross-sectional community-based survey. World J Mens Health. 2012;30:131-7. [PubMed | Full Text]
15. Johnson TV, Abbasi A, Ehrlich SS, et al. Patient misunderstanding of the individual questions of the American Urological Association symptom score. J Urol. 2008;179:2291-4. [PubMed]
16. Plante M, Corcos J, Gregoire I. The international prostate symptom score: physician versus self-administration in the quantification of symptomatology. Urology. 1996;47:326-8. [PubMed]
17. Bozlu M, Doruk E, Akbay E. Effect of administration mode (patient vs physician) and patient’s educational level on the Turkish version of the International Prostate Symptom Score. Int J Urol. 2002;9:417-21. [PubMed]
18. Wessels SG, Heyns CF. Prospective evaluation of a new visual prostate symptom score, the international prostate symptom score, and uroflowmetry in men with urethral stricture disease. Urology. 2014;83(1):220-4. [PubMed]
19. Ceylan Y, Gunlusoy B, Degrirmenci T, et al. Is new visual prostate symptom score useful as international prostate symptom score in the evaluation of men with lower urinary tract symptoms? A prospective comparision of 2 symptom scores in Turkish society. Urology. 2015;85:653-8. [PubMed]
This work is licensed under a Creative Commons Attribution 4.0 International License.
JNMA allow to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose. The author(s) are allowed to retain publishing rights without restrictions. The JNMA work is licensed under a Creative Commons Attribution 4.0 International License. More about Copyright Policy.